U.S. tariffs on generics
Potential tariffs on pharmaceutical imports could impact margins; management is working with customers to ensure supply continuity but uncertainty remains.
high · analyst_question
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
REVLIMID revenue cliff in January 2026
Exclusivity ends in January 2026, leading to significant revenue decline; management expects to offset through growth in other segments but risk remains.
high · management_commentaryGross margin volatility from one-off costs
Q4 gross margin fell 300 bps due to manufacturing overhead and lower milestone income; while management considers it one-off, recurrence could pressure margins.
medium · data_observationSemaglutide competition in Canada
Multiple players may launch generic semaglutide in Canada, leading to price erosion and lower-than-expected market share for Dr. Reddy's.
medium · analyst_question